Parbendazole is a potent inhibitor of microtubule assembly, destabilizes tubulin, with an EC50 of 530 nM, and exhibits a broad-spectrum anthelmintic activity[4]. Parbendazole (2-10 μM) inhibits the assembly of microtubules dose-dependently, with an IC50 of 3 μM. Parbendazole (2-20 μM)-treated cells show an complete absence of microtubules in Vero cells[5]. Parbendazole (up to 10 μM) inhibits the growth of CLd-AXE myxamoebae. Parbendazole (2-5 μM) potently inhibits tubulin purified from the wild-type myxamoebae[6]. Parbendazole causes profound cytoskeletal changes including degradation of microtubules and increased focal adhesions. Stabilization of microtubules by pretreatment with Taxol inhibits osteoblast differentiation. Parbendazole up-regulates bone morphogenetic protein 2 (BMP-2) gene expression and activity[7].
Parbendazole 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HN6
126 nM(IC50)
72 hours
Inhibition of HNSCC cell proliferation
Acta Pharm Sin B. 2022 May;12(5):2429-2442
Primary rat OPCs
0.02 µM
3 days
Significantly induced the number of MBP-positive cells
EBioMedicine. 2021 Mar;65:103276
Primary rat OPCs
0.02 µM
6 days
Significantly increased MOG protein expression
EBioMedicine. 2021 Mar;65:103276
CAL-27
270 nM (IC50)
72 hours
Inhibition of HNSCC cell proliferation
Acta Pharm Sin B. 2022 May;12(5):2429-2442
Fadu
153 nM(IC50)
72 hours
Inhibition of HNSCC cell proliferation
Acta Pharm Sin B. 2022 May;12(5):2429-2442
Oligodendrocyte precursor cells (OPCs)
0.02 µM
3 days
Enhanced MBP and CC1 expression, promoting oligodendrocyte differentiation
Int J Mol Sci. 2023 Jun 30;24(13):10972
Human fetal OPCs
0.002 µM and 0.02 µM
4 and 6 days
Elevated the percentage of GC-positive cells
EBioMedicine. 2021 Mar;65:103276
NG2+ cells
0.02 µM
4 or 8 days
Promoted differentiation of NG2+ cells into oligodendrocytes and reduced GFAP expression
Int J Mol Sci. 2023 Jun 30;24(13):10972
AML-PDX cells
100 nM
48 hours
To evaluate the differentiation-inducing effects of PBZ on AML-PDX cells, results showed PBZ significantly increased monocyte marker expression and induced apoptosis.
Commun Biol. 2024 Jan 24;7(1):123
21 AML cell lines
100 nM
48 hours
To assess the differentiation-inducing effects of PBZ on various AML cell lines, results showed PBZ significantly increased CD11b and CD14 expression and induced apoptosis.
Commun Biol. 2024 Jan 24;7(1):123
THP-1 cells
0.1 µM
48 hours
To evaluate the induction of monocytic differentiation in THP-1 cells by PBZ, results showed PBZ significantly increased CD11b and CD14 expression at low concentrations.
Commun Biol. 2024 Jan 24;7(1):123
Human mesenchymal stromal cells (hMSCs)
4 µM
7 days
To assess alkaline phosphatase activity, mineralization, and bone marker gene expression. Results showed that Parbendazole significantly increased ALP activity, mineralization, and expression of bone marker genes (ALPL, IBSP, SPP1).
Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12711-6
Human embryonic lung fibroblasts
0.1 µg/ml
7 days
To evaluate the inhibitory effect of Parbendazole on the proliferation of Pneumocystis carinii, results showed Parbendazole effectively inhibited proliferation at 0.1 µg/ml
To evaluate the anti-leukemic effects of PBZ in vivo on AML-PDX cells, results showed PBZ significantly reduced chimerism levels and prolonged mouse survival.
Commun Biol. 2024 Jan 24;7(1):123
C57BL/6 mice
Cuprizone-induced demyelination model of corpus callosum
Intraperitoneal injection
20 mg/kg
Daily for 17 days
Enhanced spontaneous remyelination, increased PLP-positive area and mature oligodendrocyte numbers
搜索
